Skip to main content
. Author manuscript; available in PMC: 2021 Sep 8.
Published in final edited form as: Nat Cancer. 2020 Jan 20;1(2):176–183. doi: 10.1038/s43018-019-0011-0

Fig. 2: ctDNA changes during therapy are associated with outcomes in NSCLC patients treated with chemoradiation therapy (CRT) and consolidation immune checkpoint inhibition (CICI).

Fig. 2:

a, Event chart showing timing of therapy, progression based on RECIST 1.1 evaluation of imaging, and results of ctDNA testing for each patient in the CICI cohort. b, Proportion of patients with ctDNA detected or not detected pretreatment, pre-CICI, and early on-CICI in the CICI cohort who developed progressive disease during follow-up. The number of patients in each group is displayed on the graph. P values were calculated using two-sided Fisher’s exact tests. c, Kaplan-Meier analysis of freedom from progression in the CICI cohort stratified by ctDNA detection in the early on-CICI sample (n=15 not detected, n=7 detected). P value was calculated using a two-sided log-rank test.